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Dear Editor,
We read with great interest the original paper by Shen et al1 about “Research on values of 
GDF-15 level in the diagnosis of primary liver cancer and evaluation of chemotherapeutic (CT) 
effect”. Primary liver cancer represents the most common primary cancer and despite the advances 
in oncological and surgical treatments, hepatocellular carcinoma (HCC) is still a global burden, 
representing the third cancer-related cause of death worldwide2-5. The objective of the authors 
was to investigate the values of growth differentiation factor-15 (GDF-15) level in the diagnosis 
of primary liver cancer and evaluation of chemotherapeutic effect. According to English literature 
we know that GDF-15 is a member of the transforming growth factor β (TGF-β) superfamily. It 
has been verified as a regulator in a variety of biological processes and cellular functions, such as 
cell apoptosis, differentiation and proliferation. Recently, multiple studies reported that GDF-15 
was elevated in several cancers, including pancreatic ductal adenocarcinoma, endometrial cancer, 
colorectal cancer and gastric cancer. The expression of GDF-15 in tumor tissues and effusion was 
negatively correlated with the survival of ovarian cancer. Moreover, its over-expression promoted 
tumorigenesis of prostate carcinoma cells. Regarding the HCC, serum GDF-15 level was significantly 
increased in patients with HCC and GDF-15 could be served as a serum biomarker in HCC6. The 
early diagnosis of liver cancer represents a crucial aspect to improving the treatment effect on 
liver cancer and prolonging overall survival of patients and it is well known that a multidisciplinary 
panel should provide a tailored approach for each patient, considering both guideline indications 
and patient-specific characteristics, enhancing the hospital-specific best practice. In this context 
the serum value of GDF-15 could have a decisive role for differential diagnosis between primary 
liver cancer and benign lesion and to evaluate the response to CT. The authors reported different 
results about the values of serum GDF-15 level between 92 patients with primary liver cancer 
and a control group with benign liver disease, evidencing significant differences between two 
groups with higher value in primary liver cancer. Moreover, the GDF-15 value is directly related 
to stage of primary liver cancer. In the next future is desirable that the contemporary use of GDF-
15, liver ultrasound, MRI or CT liver scanner and alpha-fetoprotein could improve the accuracy in 
primary liver cancer, especially at the initial stage and in differential diagnosis between benign 
and malignant liver lesion. Regarding the role about the response to treatment is interesting to 
observe that patients with progressive disease have higher serum GDF-15 level than those with 
partial remission and stable disease. Is this data super-imposable to serum AFP level in responder 
cancer patients? Moreover, we know that many serum tumor markers, such as Cea, Ca 19.9, Ca 
125, Ca 15.3, Cromogranina A, Bhcg and PSA7,8 can be influenced by non-malignant disease and 
could be interesting to know if GDF-15 is influenced by non malignant liver disease. In fact, Liu et 
al9 found that GDF-15 expression is associated with the hepatitis-related liver disease and could be 
interesting to know if there are some differences in presence of malignant lesions and chronic or 
infection10 liver disease. Have the authors tried the value of the serum GDF-15 in non-malignant 
liver disease? In conclusion, we think that this kind of study is important to improve the knowledge 
about early diagnosis for primary liver cancer and in a particular setting of patients such as those 
in CT treatment to evaluate the response to treatment.
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